European Medicines Agency grants Atara Biotherapeutics accelerated assessment of tab-cel for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease

Atara Biotherapeutics

27 September 2021 - Atara on track to submit MAA in November 2021.

Atara Biotherapeutics today announced the CHMP of the EMA has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.

Read Atara Biotherapeutics press release

Michael Wonder

Posted by:

Michael Wonder